Signs of inflammatory bowel disease (IBD) activity, shorter duration of IBD, and previous corticosteroid use and hospitalisation were associated with Clostridioides difficile infection in patients ...

Vedanta Biosciences has “significantly reduced” its headcount to channel its remaining resources to its lead live bacteria ...

The study of Clostridium difficile infection (CDI) continues to reveal intricate details of its pathogenesis, epidemiology and potential novel therapies. Research has elucidated how the bacterium, ...

Recurrent C. diff infection is when you contract a C. diff infection 2 to 8 weeks after completing treatment for a previous one. C. diff relapse is a recurrence of the same strain, while reinfection ...

Antibiotic use in the outpatient setting is a significant risk factor for contracting Clostridium difficile outside of a healthcare environment, according to a study published in the journal Open ...

Clostridium difficile infection rates in many healthcare facilities have not declined despite an increase in activities targeting this infection, according to a survey by the Association for ...

An infection with Clostridioides difficile (or C. diff in the trade) that occurs 72 hours after admission to the hospital is considered hospital-acquired. Medicare penalizes hospitals financially if ...

Please provide your email address to receive an email when new articles are posted on . However, this finding did not reach statistical significance, the researchers noted. “This is the first ...

Clostridium difficile is an unpleasant, sometimes severe, and potentially lethal infection. It is an enteric pathogen whose armory involves the production of a toxin leading to gut dysphoria and ...

FMT restores gut microbiota balance by transferring stool from healthy donors, mainly for recurrent C. difficile infections. Recent data shows FMT's high efficacy in preventing recurrent C. difficile, ...

STATEN ISLAND, N.Y., Dec. 9, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule ...